 Radioimmunotherapy
"Radioimmunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
| Descriptor ID |
D016499
|
| MeSH Number(s) |
E02.095.465.425.750 E02.186.750 E02.815.520
|
| Concept/Terms |
Radioimmunotherapy- Radioimmunotherapy
- Radioimmunotherapies
- Immunoradiotherapy
- Immunoradiotherapies
|
Below are MeSH descriptors whose meaning is more general than "Radioimmunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Radioimmunotherapy".
This graph shows the total number of publications written about "Radioimmunotherapy" by people in this website by year, and whether "Radioimmunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Radioimmunotherapy" by people in Profiles.
-
Bickett TE, Knitz M, Darragh LB, Bhatia S, Van Court B, Gadwa J, Bhuvane S, Piper M, Nguyen D, Tu H, Lenz L, Clambey ET, Barry K, Karam SD. FLT3L Release by Natural Killer Cells Enhances Response to Radioimmunotherapy in Preclinical Models of HNSCC. Clin Cancer Res. 2021 11 15; 27(22):6235-6249.
-
Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019 12 01; 111(12):1339-1349.
-
Getsuwan S, Wiromrat P, Panamonta O, Panamonta M, Paireepinas S. Effectiveness and Safety of Radioactive Iodine Therapy in Childhood Graves? Disease in Khon Kaen, Thailand. J Med Assoc Thai. 2016 Aug; 99 Suppl 5:S112-9.
-
Miller BW, Frost SH, Frayo SL, Kenoyer AL, Santos E, Jones JC, Green DJ, Hamlin DK, Wilbur DS, Fisher DR, Orozco JJ, Press OW, Pagel JM, Sandmaier BM. Quantitative single-particle digital autoradiography with a-particle emitters for targeted radionuclide therapy using the iQID camera. Med Phys. 2015 Jul; 42(7):4094-105.
-
Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):916-46.
-
Krishnan A, Palmer JM, Tsai NC, Simpson JR, Nademanee A, Raubitschek A, Thomas SH, Forman SJ. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant. 2012 Mar; 18(3):441-50.
-
Bischof Delaloye A, Conti PS, Gisselbrecht C, Gregory SA. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. Oncologist. 2009; 14 Suppl 2:52-4.
-
Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May; 8(5):717-32.
-
Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. Radiology. 2008 Mar; 246(3):895-902.
-
Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A. Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Sep; 7(8):514-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|